The REMAP study
Research type
Research Study
Full title
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI): The REMAP study
IRAS ID
206829
Contact name
Vicky Goh
Contact email
Sponsor organisation
King's College London
Duration of Study in the UK
3 years, 0 months, 0 days
Research summary
Renal cell (kidney) cancer has a poor outcome as the cancer will have spread beyond the kidney (be metastatic) at diagnosis in up to one third of patients, with another third developing metastases subsequently. New treatments for kidney cancer have shown promise. This imaging study aims to improve how we identify if patients are responding to treatment or not using a new imaging test (positron emission tomography and magnetic resonance imaging PET/MRI). This will allow doctors to change treatment if appropriate.
The project will involve eligible patients with metastatic renal cell cancer undergoing three additional scans alongside their usual imaging test (computed tomography (CT) scans) that is used to guide treatment. The PET/MRI will happen before treatment and at approximately 12 and 24 weeks into treatment. The PET/MRI takes approximately one hour and is a safe procedure. It combines a PET and MRI scan of the whole body. It involves an injection of a small amount of 18-fludeoxyglucose (FDG) (a radioactive form of sugar and contrast (gadolinium) which shows up the cancer better. Changes in size, FDG uptake and contrast enhancement will help us determine if the treatment is working or not.
This study will take place at the PET centre at St. Thomas’ hospital London and is funded by Cancer Research UK.REC name
London - South East Research Ethics Committee
REC reference
16/LO/1499
Date of REC Opinion
19 Oct 2016
REC opinion
Further Information Favourable Opinion